Leucovorin and 5-FU

Phase 3Small molecule

Leucovorin and 5-FU is one of 88 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

Colorectal CancerNot yet recruiting

Metastatic Colorectal CancerPhase 3

Recruiting

Colorectal CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

34 2

Vectibix

Amgen

Phase 3

32 3

Keytruda

Merck & Co.

Phase 3

25 4

Bayer Aspirin

Bayer

Phase 3

7 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 6

XL092

Roche

Phase 3

1 7

TAS 102

Taiho Oncology, Inc.

Phase 3

8 8

5-Fu

TToray Industries, Inc

Phase 3

3 9

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

Leucovorin and 5-FU

AAkeso

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Metastatic Colorectal Cancer

NCT06951503

Q1 2030

ApprovedNot yet recruiting

Colorectal Cancer

NCT07094893

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Recruiting·AAkeso·Phase 3·NCT06951503·560 enrolled

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Unknown status·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 2·NCT03880877·153 enrolled

Colorectal Cancer1 trial

A Biomarker Enrichment Trial of Anti-EGFR Agents in Patients With Advanced Colorectal Cancer (aCRC) With Wild-type RAS and Right Primary Tumour Location (Right-PTL).

Not yet recruiting·GGruppo Oncologico del Nord-Ovest·Approved·NCT07094893·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Leucovorin and 5-FU. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leucovorin and 5-FU compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leucovorin and 5-FU. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akeso company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAkeso

Leucovorin and 5-FU

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q1 2030

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News